Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC
Specialties >>
AML
Bladder Cancer
Breast Cancer
CAR T-Cell Therapy
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Genomic Testing
GI Cancers
GIST
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Liquid Biopsies
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Thyroid Cancers
More >>
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
Select a Topic:
– Select a topic –
Bladder Cancer
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Follicular Lymphoma
General Cancer
Graft versus Host Disease
Kidney Cancer
Lung Cancer
Multiple Myeloma
Non-Hodgkin Lymphoma
Prostate Cancer
Skin Cancer
Browse by Series:
– Select a Series –
New Strategy for Unmet Need in Relapsed/Refractory DLBCL
Novel Maintenance Combination in Advanced Ovarian Cancer
New Approval for the Nonmetastatic CRPC Population
New Outcomes in Acute Graft-versus-Host Disease
What`s New in Acute Graft-versus-Host Disease?
Emerging Data in R/R DLBCL
Advances in Steroid-Refractory Acute GVHD
Reducing Early Disease Progression in Follicular Lymphoma
Advances in Metastatic Castration-Sensitive Prostate Cancer
Addressing Unmet Needs in HER2-Positive Metastatic Breast Cancer
Daratumumab as Frontline Treatment for Multiple Myeloma
Novel IL-2 Based Combinations for Bladder Cancer
Real-World Data for Chemotherapy Treatment in Metastatic Triple-Negative Breast Cancer
Treatment Options for Stage III Unresectable NSCLC After Chemoradiotherapy
New Immunotherapeutic Agents Broaden Treatment Options for Chronic Lymphocytic Leukemia
PI3K Inhibitors in R/R Follicular Lymphoma
Treatment Options for Recurrent Metastatic Triple-Negative Breast Cancer
SIRT for Nonresectable CRC With Liver Metastases
Systemic Treatment of Metastatic Cutaneous Squamous Cell Carcinoma
Evolving NSCLC Treatment Paradigm
Upfront Therapy for mRCC
NKTR-214 & Nivolumab: Synergistic Activity Across Tumor Types
Endocrine Therapy for HR+ Metastatic Breast Cancer
PARP Inhibitors in Ovarian Cancer
Changing Treatment Landscape in Nonmetastatic CRPC
Immunotherapy in Unresectable Locally Advanced NSCLC
Treatment of Newly Diagnosed Advanced Kidney Cancer
Immunotherapy Use in Newly Diagnosed NSCLC
IMiD Sequencing in Multiple Myeloma
Addressing Unmet Needs in mRCC
mRCC: Factors for Choosing Second-Line Therapy
Role for Everolimus in mRCC Treatment?
mRCC: Decision Making for VEGF TKIs
Role of PD-L1 Status in mRCC
mRCC: Risk Status and Other Factors for Therapy
Factors for Choosing Frontline mRCC Treatment
mRCC: Impact of CABOSUN and CheckMate-214
JTT Articles
Participating Practices Commend CMS for OCM Changes
The Role of Liquid Biopsy in NSCLC Continues to Emerge
Rare Incidence of ICI-Related Hepatotoxicity Frequently Ends in Treatment Discontinuation
>> View Peer-Reviewed Articles
